个人中心 - 老虎社区

CathayWood

IP属地：未知

帖子 · 69帖子 · 69
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- CathayWoodCathayWood
  ·2021-06-09
  $DraftKings Inc.(DKNG)$stonks
  669 评论
  1
  分享
  举报
- CathayWoodCathayWood
  ·2021-06-09
  Comment
  S&P 500 closes little changed as "meme stocks" extend rally
  NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of c
  S&P 500 closes little changed as "meme stocks" extend rally
  665 1
  4
  分享
  举报
- CathayWoodCathayWood
  ·2021-06-08
  $Zillow(Z)$pls stonkk
  742 评论
  1
  分享
  举报
- CathayWoodCathayWood
  ·2021-06-08
  Comment
  FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades
  (June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer
  FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades
  600 评论
  1
  分享
  举报
- CathayWoodCathayWood
  ·2021-06-05
  $Zillow(Z)$pls stonk
  658 1
  3
  分享
  举报
- CathayWoodCathayWood
  ·2021-06-01
  $SIA LTD R1(1P2R.SI)$stonks
  716 评论
  1
  分享
  举报
- CathayWoodCathayWood
  ·2021-06-01
  Comment
  These are Wall Street’s top analysts favorite stocks heading into June
  With May coming to a close, Wall Street analysts are fine tuning their recommendations as COVID-19 v
  These are Wall Street’s top analysts favorite stocks heading into June
  1,096 1
  2
  分享
  举报
- CathayWoodCathayWood
  ·2021-05-31
  $Twilio(TWLO)$comment
  1,076 评论
  3
  分享
  举报
- CathayWoodCathayWood
  ·2021-05-31
  $SINGAPORE AIRLINES LTD(C6L.SI)$keep dropping
  1,042 评论
  5
  分享
  举报
- CathayWoodCathayWood
  ·2021-05-29
  $Tesla Motors(TSLA)$stonk
  804 1
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3577751115441703","uuid":"3577751115441703","gmtCreate":1614659485392,"gmtModify":1619169734618,"name":"CathayWood","pinyin":"cathaywood","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":5,"tweetSize":69,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.23%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":180177157,"gmtCreate":1623196835879,"gmtModify":1631884911121,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DKNG\">$DraftKings Inc.(DKNG)$</a>stonks","listText":"<a href=\"https://laohu8.com/S/DKNG\">$DraftKings Inc.(DKNG)$</a>stonks","text":"$DraftKings Inc.(DKNG)$stonks","images":[{"img":"https://static.tigerbbs.com/5b0ac68895746eba7632586e2658453f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/180177157","isVote":1,"tweetType":1,"viewCount":669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":180176236,"gmtCreate":1623196720325,"gmtModify":1634035999901,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/180176236","repostId":"1128909306","repostType":4,"repost":{"id":"1128909306","kind":"news","pubTimestamp":1623193560,"share":"https://ttm.financial/m/news/1128909306?lang=&edition=full","pubTime":"2021-06-09 07:06","market":"us","language":"en","title":"S&P 500 closes little changed as \"meme stocks\" extend rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1128909306","media":"reuters","summary":"NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of c","content":"<p>NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of clear market catalysts kept institutional investors on the sidelines, while retail traders fueled the ongoing meme stocks rally.</p><p>All three major U.S. stock indexes ended the range-bound session near flat or higher, with the S&amp;P 500 and the Dow closing within about 0.5% of record highs.</p><p>The tech-laded Nasdaq Composite fared best, with Amazon.com Inc and Apple Inc providing the biggest boost.</p><p>“We’re waiting for inflation numbers, waiting for more from the (Federal Reserve), waiting for earnings season,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “There’s not a lot motivating the market today.”</p><p>“We’re in this twilight zone until probably right after the Fourth of July, when we see earnings season kick in,” Nolte added.</p><p>The CBOE volatility index, a measure of investor anxiety, touched its lowest level in over a year.</p><p>Smallcaps, once again buoyed by the ongoing meme stock retail frenzy, were outperforming their larger counterparts.</p><p>Clover Health Investments seized top billing among meme stocks, surging 85.8%, the biggest percentage winner in the Nasdaq.</p><p>Other stocks whose recent explosive trading volumes have been attributed to social media buzz, including GameStop Corp, Bed Bath &amp; Beyond Inc, Workhorse Group and others, ended the session between 7% and 12% higher.</p><p>“(Meme stocks) are where the action is, but you flip it over and look crypto and that’s a mess,” Nolte said. “Now the meme stocks are taking over from crypto as the place to be and it’s all a consequence of very easy monetary policy.”</p><p>Reports from the U.S. Labor Department and National Federation of Independent Business appeared to confirm a labor shortage even as demand roars back to life, which could put upward pressure on wages, a precursor to wider inflation.</p><p>Market participants look to Thursday’s consumer price index data for further clues regarding inflation, and how it could influence the Federal Reserve’s timetable for tightening its monetary policy.</p><p>The Dow Jones Industrial Average fell 30.42 points, or 0.09%, to 34,599.82; the S&amp;P 500 gained 0.74 points, or 0.02%, at 4,227.26; and the Nasdaq Composite added 43.19 points, or 0.31%, at 13,924.91.</p><p>Of the 11 major sectors in the S&amp;P 500, consumer discretionary enjoyed the biggest percentage gain, and utilities suffered the largest loss.</p><p>Sales of Tesla Inc’s China-made electric cars jumped in May by 29%, marking a 177% year-on-year increase, according to the China Passenger Car Association. The stock erased initial gains on the news to close down 0.3%.</p><p>Boeing Co shares were boosted by Southwest Airlines’ announcement that it had ordered 34 new 737 MAX aircraft, but the planemaker’s shares pared gains to end the session flat.</p><p>GameStop, the company most closely associated with the Reddit-driven short squeeze phenomenon, is expected to report quarterly results after markets close on Wednesday.</p><p>Advancing issues outnumbered decliners on the NYSE by a 1.74-to-1 ratio; on Nasdaq, a 1.66-to-1 ratio favored advancers.</p><p>The S&amp;P 500 posted 54 new 52-week highs and one new low; the Nasdaq Composite recorded 172 new highs and 16 new lows.</p><p>Volume on U.S. exchanges was 11.82 billion shares, compared with the 10.75 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 closes little changed as \"meme stocks\" extend rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 closes little changed as \"meme stocks\" extend rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 07:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-closes-little-changed-as-meme-stocks-extend-rally-idUSL2N2NQ2NX><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of clear market catalysts kept institutional investors on the sidelines, while retail traders fueled the...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-closes-little-changed-as-meme-stocks-extend-rally-idUSL2N2NQ2NX\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","CLOV":"Clover Health Corp"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-closes-little-changed-as-meme-stocks-extend-rally-idUSL2N2NQ2NX","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128909306","content_text":"NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of clear market catalysts kept institutional investors on the sidelines, while retail traders fueled the ongoing meme stocks rally.All three major U.S. stock indexes ended the range-bound session near flat or higher, with the S&P 500 and the Dow closing within about 0.5% of record highs.The tech-laded Nasdaq Composite fared best, with Amazon.com Inc and Apple Inc providing the biggest boost.“We’re waiting for inflation numbers, waiting for more from the (Federal Reserve), waiting for earnings season,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “There’s not a lot motivating the market today.”“We’re in this twilight zone until probably right after the Fourth of July, when we see earnings season kick in,” Nolte added.The CBOE volatility index, a measure of investor anxiety, touched its lowest level in over a year.Smallcaps, once again buoyed by the ongoing meme stock retail frenzy, were outperforming their larger counterparts.Clover Health Investments seized top billing among meme stocks, surging 85.8%, the biggest percentage winner in the Nasdaq.Other stocks whose recent explosive trading volumes have been attributed to social media buzz, including GameStop Corp, Bed Bath & Beyond Inc, Workhorse Group and others, ended the session between 7% and 12% higher.“(Meme stocks) are where the action is, but you flip it over and look crypto and that’s a mess,” Nolte said. “Now the meme stocks are taking over from crypto as the place to be and it’s all a consequence of very easy monetary policy.”Reports from the U.S. Labor Department and National Federation of Independent Business appeared to confirm a labor shortage even as demand roars back to life, which could put upward pressure on wages, a precursor to wider inflation.Market participants look to Thursday’s consumer price index data for further clues regarding inflation, and how it could influence the Federal Reserve’s timetable for tightening its monetary policy.The Dow Jones Industrial Average fell 30.42 points, or 0.09%, to 34,599.82; the S&P 500 gained 0.74 points, or 0.02%, at 4,227.26; and the Nasdaq Composite added 43.19 points, or 0.31%, at 13,924.91.Of the 11 major sectors in the S&P 500, consumer discretionary enjoyed the biggest percentage gain, and utilities suffered the largest loss.Sales of Tesla Inc’s China-made electric cars jumped in May by 29%, marking a 177% year-on-year increase, according to the China Passenger Car Association. The stock erased initial gains on the news to close down 0.3%.Boeing Co shares were boosted by Southwest Airlines’ announcement that it had ordered 34 new 737 MAX aircraft, but the planemaker’s shares pared gains to end the session flat.GameStop, the company most closely associated with the Reddit-driven short squeeze phenomenon, is expected to report quarterly results after markets close on Wednesday.Advancing issues outnumbered decliners on the NYSE by a 1.74-to-1 ratio; on Nasdaq, a 1.66-to-1 ratio favored advancers.The S&P 500 posted 54 new 52-week highs and one new low; the Nasdaq Composite recorded 172 new highs and 16 new lows.Volume on U.S. exchanges was 11.82 billion shares, compared with the 10.75 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":665,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114480078,"gmtCreate":1623087352394,"gmtModify":1631888369150,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Z\">$Zillow(Z)$</a>pls stonkk","listText":"<a href=\"https://laohu8.com/S/Z\">$Zillow(Z)$</a>pls stonkk","text":"$Zillow(Z)$pls stonkk","images":[{"img":"https://static.tigerbbs.com/deb25696209f47ebffa12f7d6e6c6465","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114480078","isVote":1,"tweetType":1,"viewCount":742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":114417618,"gmtCreate":1623087323234,"gmtModify":1634037090766,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114417618","repostId":"1108033863","repostType":4,"repost":{"id":"1108033863","kind":"news","pubTimestamp":1623087360,"share":"https://ttm.financial/m/news/1108033863?lang=&edition=full","pubTime":"2021-06-08 01:36","market":"us","language":"en","title":"FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades","url":"https://stock-news.laohu8.com/highlight/detail?id=1108033863","media":"cnbc","summary":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer","content":"<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1108033863","content_text":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine for the disease in nearly two decades.The FDA's decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.\"We are well-aware of the attention surrounding this approval,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a press release. \"We understand that Aduhelm has garnered the attention of the press, the Alzheimer's patient community, our elected officials, and other interested stakeholders.\"\"With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,\" Cavazzoni added.Alzheimer’s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with the disease, according toestimates by the Alzheimer’s Association.By 2050, that number is projected to rise to nearly 13 million, according to the group.There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer’s, which is the sixth leading cause of death in the United States. The U.S. agency has approved Alzheimer’s drugs aimed at helping symptoms, not actually slowing the disease itself.Federal regulators have faced intense pressure from friends and family members of Alzheimer’s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.In March of 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.Shares of Biogen soared in Novemberafter it won backing from FDA staff, who said the company showed highly “persuasive” evidence aducanumab was effective and that it had “an acceptable safety profile that would support use in individuals with Alzheimer’s disease.”But two days later, a panel of outside experts that advises theU.S. agency unexpectedly declined to endorsethe experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger data set showed that aducanumab “reduced clinical decline in patients with early Alzheimer’s disease.”Alzheimer’s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove that the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.Some doctorshave said they won’t prescribethe drug if it does reach the market, because of the mixed data package supporting the company’s application.Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged that the data isn’t perfect. However, they argue that it could help some patients with Alzheimer’s, a progressive and debilitating disease.Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug, according to Reuters.The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.The U.S. agency said Monday it determined there was “substantial evidence” the drug helps patients.“As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease,” it said.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":112028372,"gmtCreate":1622826937696,"gmtModify":1631888369155,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Z\">$Zillow(Z)$</a>pls stonk","listText":"<a href=\"https://laohu8.com/S/Z\">$Zillow(Z)$</a>pls stonk","text":"$Zillow(Z)$pls stonk","images":[{"img":"https://static.tigerbbs.com/6ca0fc31b7e268ddd021db0ea34fbd85","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/112028372","isVote":1,"tweetType":1,"viewCount":658,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":119626888,"gmtCreate":1622543785444,"gmtModify":1631889071313,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/1P2R.SI\">$SIA LTD R1(1P2R.SI)$</a>stonks","listText":"<a href=\"https://laohu8.com/S/1P2R.SI\">$SIA LTD R1(1P2R.SI)$</a>stonks","text":"$SIA LTD R1(1P2R.SI)$stonks","images":[{"img":"https://static.tigerbbs.com/1809bdbe83e935a69cb471769ae0a4d2","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/119626888","isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":119621745,"gmtCreate":1622543738987,"gmtModify":1634100654389,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119621745","repostId":"1143634909","repostType":4,"repost":{"id":"1143634909","kind":"news","pubTimestamp":1622418963,"share":"https://ttm.financial/m/news/1143634909?lang=&edition=full","pubTime":"2021-05-31 07:56","market":"us","language":"en","title":"These are Wall Street’s top analysts favorite stocks heading into June","url":"https://stock-news.laohu8.com/highlight/detail?id=1143634909","media":"CNBC","summary":"With May coming to a close, Wall Street analysts are fine tuning their recommendations as COVID-19 v","content":"<div>\n<p>With May coming to a close, Wall Street analysts are fine tuning their recommendations as COVID-19 vaccinations pave the way for further economic re-opening this summer.We used TipRanks analyst ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/30/wall-street-analysts-say-buy-stocks-deere-advanced-micro-devices.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are Wall Street’s top analysts favorite stocks heading into June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are Wall Street’s top analysts favorite stocks heading into June\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 07:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/30/wall-street-analysts-say-buy-stocks-deere-advanced-micro-devices.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With May coming to a close, Wall Street analysts are fine tuning their recommendations as COVID-19 vaccinations pave the way for further economic re-opening this summer.We used TipRanks analyst ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/30/wall-street-analysts-say-buy-stocks-deere-advanced-micro-devices.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATRC":"AtriCure公司","AMED":"阿米斯医疗","DE":"迪尔股份有限公司","AEIS":"先进能源工业公司","AMD":"美国超微公司"},"source_url":"https://www.cnbc.com/2021/05/30/wall-street-analysts-say-buy-stocks-deere-advanced-micro-devices.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1143634909","content_text":"With May coming to a close, Wall Street analysts are fine tuning their recommendations as COVID-19 vaccinations pave the way for further economic re-opening this summer.We used TipRanks analyst forecasting service to pinpoint stocks earning bullish support from the Street, narrowing our search to only calls made by the best-performing analysts. These are the analysts with the highest success rate and average return per rating, taking into consideration the number of ratings published by each analyst.Here are top Wall Street analysts' five favorite stocks heading into June:Advanced Micro DevicesNorthland Capital analyst Gus Richard says it's to infinity and beyond for Advanced Micro Devices. In line with this optimistic take, the five-star analyst reiterated a Buy rating and $116 price target.Richard believes that the semiconductor name will have a solid Q2, but argues the real question is whether PC demand will slow as the economy re-opens. According to the analyst, the answer is yes, but points out that $AMD(AMD)$’s “better products” are helping it to take market share from Intel.“One of the most difficult markets to penetrate is the corporate client. In CY19 Intel was short on 14nm capacity and late on 10nm and this limited its ability to meet demand opening the door for AMD in the corporate market. We estimate that AMD currently has a 5% to 7% share of the higher-margin corporate client market and expect its share to accelerate as corporations dual source,” Richard explained.Additionally, based on Intel’s recent results and the analyst’s industry checks, Intel has been focused on low-end Chromebooks, and “these dynamics bode well for a strong 2H for AMD in the client market,” in Richard’s opinion.With this in mind, Richard argues that over the next few years, AMD’s revenue share in the PC clients market will reach around 50%, from 20% currently. It also is in the second year of a game console product cycle, which the analyst believes could lead to an improvement in gross margins for this segment.It should also be noted thatAMDhas an advantage in the x86 server space. “We believe leadership in the x86 market is driven primarily by process technology and to a lesser extent design differentiation. INTC is chasing government money to build foundries in the US putting it into competition with TSMC. While INTC has struck a longterm supply agreement with TSMC they are also becoming a competitor to TSMC. It is in TSMC’s best interest to favor AMD over INTC as it will get all of AMD’s lead edge logic business,” Richard commented.Landing a top 40 spot on TipRanks’ list of best-performing analysts, Richard boasts a 71% success rate and 33.8% average return per rating.AmedisysOperating in the healthcare services space,Amedisys offers home healthcare (HH), hospice services and disease management programs.According to Oppenheimer’s Michael Wiederhorn, the company’s “growth story remains on track,” prompting the analyst to maintain a Buy rating. In addition, he left the $325 price target as is.“We hosted meetings with Amedisys and believe the company remains well-positioned for growth in the post-pandemic era, driven by organic opportunities as it bulks up its BD staff and leverages opportunities to further penetrate existing markets with its sizable hospice platform, which included ~$600 million in acquired hospice revenues,” Wiederhorn noted.Across both of its main segments, trends have been bouncing back, with elective procedures moving toward 100% of baseline. As for the hospice business,Amedisys’ primary focus is on admissions, but Wiederhorn points out that LOS issues might have normalized.Some investors have expressed concern about labor inflation, but Wiederhorn doesn’t see this as a significant issue. The analyst tells investors that “despite the ongoing noise in the marketplace,” labor inflation is under control and management is watching the wage environment.“Amedisys has continued to generate low turnover rates (15%) that are well below the market and historical levels (40%) due in large part to its predictive analytics that identify vulnerable employees,” Wiederhorn added.When it comes to M&A, the company is “optimistic on the longer-term upside from home health M&A, as the myriad of pandemic-related benefits, including sequestration, payroll tax, Medicare accelerated payments, CARES Act money and the RAP impact, are set to expire,” says Wiederhorn. He also points out that Amedisys has made a significant effort to establish partnerships which “leverage its high quality scores.”“The company spoke positively regarding its SNF @ Home Partnership with Sound Physicians, which deploys some form of capitation, while its Fresenius dialysis partnership has partial capitation,” Wiederhorn stated.Thanks to his 76% success rate and 23.6% average return per rating, Wiederhorn is ranked #34 out of over 7,000 analysts tracked by TipRanks.DeereEven though Deere bumped up its outlook for 2021, Jefferies analyst Stephen Volkmann thinks these estimates “could prove conservative.” With this in mind, the top analyst reiterated a Buy rating. In addition, he gave the price target a lift, with the figure moving from $400 to $450.When trying to call Deere’s next peak, it is “complicated,” in Volkmann’s opinion. “First, management’s commentary around the cycle – both Large and Small Ag business at roughly 110-115% of mid-cycle – excludes the last supercycle and therefore undercounts the potential. Second, we estimate overall ASPs have increased 40-50% since the 2013 peak through a combination of emissions regulations, increased technology content, and normal inflation,” the analyst explained.So, what’s the bottom line? Volkmann estimates that the total potential revenue is $55 billion, and at 20% EBIT margin, this amounts to $30 in earnings power, not including additional capital employment.According to the management team at Deere, for 2021, consolidated sales are set to rise 23.5%-28.5% (compared to the previous 16%-25% estimate), with this factoring in FX and pricing tailwinds.Volkmann points out that although the company is benefitting from commodity price inflation, management has warned about a $750 million freight/logistics and material costs headwind for the rest of this year. In addition, given that the 2021 order book is filled, it might be hard for Deere to cover additional increases. That being said, the analyst argues “pricing was the standout message of the quarter, adding roughly 6 percentage points to F1H growth and 5-plus points to the full-year outlook.”What’s more, Deere is evaluating additional structural changes, with this potentially including overseas footprint consolidations and closures. Its key priorities are to streamline the organizational structure, make “more focused capital allocation decisions geared toward the higher-growth, higher-margin portion of the portfolio,” expand the aftermarket opportunity and increase Wirtgen synergies.Volkmann lands a top 100 ranking as a result of his 74% success rate and 25.8% average return per rating.ZscalerCalling Zscaler’s latest quarterly performance “another jaw dropper,” Wedbush’s Daniel Ives remains very much with the bulls. To this end, the analyst kept a Buy rating and $240 price target on the cloud-based information security company.Looking at the print, billings gained 71% and surpassed the consensus estimate by 20%-plus, with Ives noting its “clear that the zero trust shift is hitting another gear of growth with ZS leading the charge.”Expounding on this, Ives stated, “While the bears and skeptics on ZS threw the company in the ‘WFH growth tailing off crew’ over the last few months, we continue to view this is a zero trust cloud transformation name that will see massive growth prospects for the foreseeable future as the company is essentially the only game in town on enterprise scale zero trust cyber security deployments.”Arguing that Zscaleris in the “drivers seat” when it comes to the cloud cyber security shift over the next ten years, Ives believes that the current IT landscape has ramped up the company’s ability to capitalize on the opportunity.“In our opinion, ZS is the best pure play in the cloud security arena, which we believe is still in the very early innings of taking off with overall hybrid cloud workloads poised to meaningfully accelerate over the coming years and in this climate could see some strategic deals moved forward as the shift to cloud outside the firewall is catalyzing a handful of key sales cycles,” Ives commented.According to the Wedbush analyst, the need to secure applications, data and consumers outside the firewall highlight the huge total addressable market.Summing it all up, Ives said, “To this point given last night’s results and our increased confidence in the ZS story, we believe a further re-rating is still in the cards over the next 12 to 18 months.”Ives’ stellar track record speaks for itself. The #73 rated analyst has delivered a 68% success rate and 30.4% average return per rating.AtriCureAtriCure has developed a portfolio of products for the surgical ablation of cardiac tissue to treat persistent atrial fibrillation (AF) in concomitant and stand-alone procedures.For BTIG analyst Marie Thibault, there are multiple reasons to be bullish on AtriCure’s long-term growth prospects. Bearing this in mind, the five-star analyst reiterated a Buy rating and a $76 price target.Recently, Thibault hosted a call with Dr. Michael Panutich, a cardiac electrophysiologist (EP) at the Hoag Heart & Vascular Institute, who has been performing the hybrid Convergent procedure, which involves endocardial catheter ablation and epicardial ablation using AtriCure’s EPi-Sense Coagulation Device, since 2017. Given that the FDA has approved the EPi-Sense device in long-standing persistent AF, Dr. Panutich believes that the number of hospitals adopting and marketing the procedure will grow.On top of this, Thibault points out that the FDA approval could make it easier to secure reimbursement, as “fewer insurers will be able to push back on the treatment as being ‘experimental’ or require a failed ablation first.”“This discussion left us with the impression that ATRC’s minimally invasive franchise is poised for robust growth, that careful training will be key to continued success with the Convergent procedure, and that the AF field will continue to be a source of clinical progress,” Thibault commented.What else is driving Thibault’s confidence? The analyst highlights the ongoing momentum for AtriClip, AtriCure’s product designed for use in the occlusion of the left atrial appendage, one of the most common sources of stroke. She is also expecting to see new verticals like cryoablation contribute to revenue generation.Thibault sports an impressive 65.8% average return per rating, helping her to earn a #127 ranking.","news_type":1,"symbols_score_info":{"AEIS":0.9,"AMD":0.9,"AMED":0.9,"ATRC":0.9,"DE":0.9}},"isVote":1,"tweetType":1,"viewCount":1096,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110128877,"gmtCreate":1622432397199,"gmtModify":1631888326589,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TWLO\">$Twilio(TWLO)$</a>comment","listText":"<a href=\"https://laohu8.com/S/TWLO\">$Twilio(TWLO)$</a>comment","text":"$Twilio(TWLO)$comment","images":[{"img":"https://static.tigerbbs.com/850879626cbf739c5eb305727415a3c4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/110128877","isVote":1,"tweetType":1,"viewCount":1076,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":110128976,"gmtCreate":1622432383295,"gmtModify":1631885596855,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>keep dropping&nbsp;","listText":"<a href=\"https://laohu8.com/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>keep dropping&nbsp;","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$keep dropping","images":[{"img":"https://static.tigerbbs.com/c94c1dc9cb9012f2d6efd659aa442a32","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/110128976","isVote":1,"tweetType":1,"viewCount":1042,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":137065042,"gmtCreate":1622270468786,"gmtModify":1634102585195,"author":{"id":"3577751115441703","authorId":"3577751115441703","name":"CathayWood","avatar":"https://static.tigerbbs.com/75bab2a33a1bab50e1246e3ff093e54a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577751115441703","idStr":"3577751115441703"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>stonk","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>stonk","text":"$Tesla Motors(TSLA)$stonk","images":[{"img":"https://static.tigerbbs.com/49e0a7bdea85438c26d3e58c9608a10e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/137065042","isVote":1,"tweetType":1,"viewCount":804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}